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Abstract
We sought to define protective mechanisms of immunity to Staphylococcus aureus and Candida albicans bloodstream
infections in mice immunized with the recombinant N-terminus of Als3p (rAls3p-N) vaccine plus aluminum hydroxide
(Al(OH3) adjuvant, or adjuvant controls. Deficiency of IFN-c but not IL-17A enhanced susceptibility of control mice to both
infections. However, vaccine-induced protective immunity against both infections required CD4+ T-cell-derived IFN-c and
IL-17A, and functional phagocytic effectors. Vaccination primed Th1, Th17, and Th1/17 lymphocytes, which produced pro-
inflammatory cytokines that enhanced phagocytic killing of both organisms. Vaccinated, infected mice had increased IFN-c,
IL-17, and KC, increased neutrophil influx, and decreased organism burden in tissues. In summary, rAls3p-N vaccination
induced a Th1/Th17 response, resulting in recruitment and activation of phagocytes at sites of infection, and more effective
clearance of S. aureus and C. albicans from tissues. Thus, vaccine-mediated adaptive immunity can protect against both
infections by targeting microbes for destruction by innate effectors.
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Introduction
Staphylococcus aureus and Candida spp. are the second and third
leading causes of bloodstream infections in hospitalized patients [1].
These organisms jointly cause at least 150,000 clinical bloodstream
infections resulting billions of dollars of health-care expenditures
and ,40,000 deaths per year in the US alone [1–4]. Identification
of immune mechanisms of protective adaptive immunity against
these organisms is critical to lay the groundwork for development of
active vaccine strategies against both organisms.
We previously reported that vaccination with the recombinant
N terminus of the candidal Als3p adhesin (rAls3p-N) with
aluminum hydroxide (Al(OH)3) adjuvant improved the survival
of mice subsequently infected intravenously with lethal inocula of
Candida albicans or methicillin resistant Staphylococcus aureus (MRSA)
[5–7]. The vaccine retained efficacy against both infections in B
cell deficient animals but not T cell deficient animals [6,7].
Furthermore, adoptive transfer of CD4+ T cells but not B220+ B
cells or immune serum improved the survival of recipient mice
infected with both organisms [6,7].
Although T cells are necessary for rAls3p-N vaccine efficacy,
lymphocytes are not capable of directly killing C. albicans or S.
aureus in culture [8,9]. Therefore, the downstream effectors of
vaccination against both organisms have remained unclear. In
contrast to lymphocytes, phagocytes kill C. albicans and S. aureus in
vitro [8,10,11] and in vivo [12–16], especially when primed with
pro-inflammatory cytokines such as interferon (IFN)-c, which is
produced by CD4+ lymphocytes. Therefore, we hypothesized that
the end effectors of rAls3p-N vaccine-mediated protection against
bloodstream infection caused by S. aureus and C. albicans were
phagocytes primed by pro-inflammatory cytokines produced by
vaccine-responsive lymphocytes. We sought to elucidate funda-
mental requirements of protective host immunity to bloodstream
infection caused by S. aureus and C. albicans.
Results
CD4+ lymphocyte-derived IFN-c was necessary for
vaccine efficacy in mice infected with either organism
We previously established that the rAls3p-N vaccine was not
effective against C. albicans iv infection in IFN-c-deficient mice [6].
We sought to determine if IFN-c was similarly required for vaccine-
mediated protection against S. aureus, and also to determine if CD4+
T cells were the required source of IFN-c production to mediate
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their wild-type, congenic controls were vaccinated with rAls3p-N
plus Al(OH)3 (vaccinated) or Al(OH)3 alone (control), and boosted
at three weeks. Two weeks following the boost, CD4+ splenic and
lymph node lymphocytes from vaccinated or control donor mice
were purified and cross-adoptively transferred to recipient mice
(IFN-c deficient donor cells were transferred to wild type recipient
mice, and visa versa). As a negative control, vaccinated or control
IFN-c knockout mice were infected without undergoing adoptive
transfer. Mice were infected via the tail-vein with C. albicans or
MRSA the day following adoptive transfer.
IFN-c-deficient mice receiving immune CD4+ lymphocytes
from vaccinated, wild type donor mice had improved survival after
either infection, whereas wild type mice receiving immune CD4+
lymphocytes from IFN-c-deficient, vaccinated donor mice did not
have improved survival (Fig. 1). Cells from control donor mice
were not effective at improving survival of recipient mice. Hence,
IFN-c produced by vaccine-primed CD4+ T cells was required for
mediating adaptive immunity against both infections.
Functional phagocytes were necessary for vaccine
efficacy in mice infected with either organism
Because lymphocyte derived pro-inflammatory cytokines, in-
cluding IFN-c, can activate phagocytes to mediate superior killing
of C. albicans or S. aureus in culture [8,11,17–22], we sought to
define the role of downstream phagocytes in adaptive immune-
mediated protection. First we vaccinated mice as above and
administered cyclophosphamide to induce neutropenia two weeks
after the boost. Two days later we infected the mice with one of
two clinical isolates of C. albicans, or with MRSA. The second
isolate of C. albicans (15563) was used because it results in a less
rapidly lethal infection than SC5314, and the diminished severity
of infection would afford the opportunity to unmask any subtle,
residual protection afforded by vaccination in the neutropenic
mice. Cyclophosphamide-induced neutropenia disrupted the
improvement in survival mediated by the vaccine against
infections caused by either strains of C. albicans and S. aureus (Fig.
2 and Fig. S1 for the 15563 strain).
We also tested vaccine efficacy in gp91
phox2/2 deficient mice,
the phagocytes of which are unable to generate superoxide and
have marked defects in microbial killing. Such mice have been
previously shown to have enhanced susceptibility to pulmonary
and intraperitoneal infection by C. albicans [23,24], but have not
been studied in the intravenous model. We performed pilot studies
to determine how susceptible to iv infection with C. albicans or S.
aureus the gp91
phox2/2 mice were. Remarkably, we found that the
100% lethal dose (LD100)o fC. albicans SC5314 was .150-fold
lower in gp91
phox2/2 mice vs. wild-type controls (,10
3 vs.
1.5610
5). The LD100 of S. aureus LAC was 2-fold lower in
gp91
phox2/2 mice vs. wild type controls (5610
6 vs. 10
7).
Subsequently, gp91
phox2/2 and wild type mice were vaccinated
with rAls3p-N plus Al(OH)3 or Al(OH)3 alone. CD4+ T cells from
vaccinated or control wild type donor mice were adoptively
transferred into gp91
phox2/2 recipient mice, and visa versa. As
well, some mice were vaccinated and infected without undergoing
adoptive transfer as positive (wild type) and negative (gp91
phox2/2)
controls for vaccine efficacy. The vaccine did not improve the
survival of gp91
phox2/2 mice infected with either organism (Fig.
3A). While CD4+ T lymphocytes from vaccinated, gp91
phox2/2
Figure 1. CD4 derived IFN-c is required for vaccine protection.
Wild type Balb/c mice were infected with 2610
5 C. albicans SC5314 or
2610
7 S. aureus LAC; IFN-c deficient mice on a Balb/c background were
infected with 10
5 C. albicans or 10
7 S. aureus. A) Wild type, n=8 mice
per group, or IFN-c deficient mice, n=7 mice per group, were
vaccinated and infected iv via the tail-vein 2 weeks after the booster
dose. *p,0.05 for wild type vaccinated vs. control by Log Rank test. B)
CD4+ T cells, 5610
6, from vaccinated or control mice were adoptively
transferred iv to recipient mice, n=8 mice per group, 24 h prior to
infection. *p,0.05 for wild type donor cells vaccinated vs. control by
Log Rank test.
doi:10.1371/journal.ppat.1000703.g001
Author Summary
The bacterium Staphylococcus aureus and the fungus
Candida are the second and third leading cause of
bloodstream infections in hospitalized patients. A vaccine
to prevent such infections would be of enormous public
health benefit. The leading hypothesis to explain why
vaccines have not been successfully developed against
these infections is that the microbes causing the infections
are highly complex, and use multiple weapons (so-called
‘‘virulence factors’’) to cause disease in humans. Therefore,
a vaccine targeting either infection would have to
neutralize many of these virulence factors at the same
time. We have been developing a vaccine that simulta-
neously targets both types of infections. Our vaccine is
based on a single virulence factor used by Candida, which
has a similar shape to virulence factors used by S. aureus.I n
the current study, we report that our vaccine induces
specialized cells in the immune system to more effectively
call in reinforcements to kill the organisms. These data
demonstrate that vaccines against both organisms can be
developed even if they do not work by neutralizing
multiple virulence factors, and therefore open the door to
a far wider array of vaccine types against both infections.
Th1/Th17 Immunity to S. aureus and C. albicans
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CD4+ T cells from vaccinated, wild-type donor mice failed to
improve the survival of gp91
phox2/2 recipient mice (Fig. 3B).
CD4+ lymphocyte-derived IL-17A was also necessary for
vaccine efficacy
The need for downstream functional phagocytes to mediate
vaccine efficacy suggested that Th17 cells, which are known to act
by recruiting phagocytes to the sites of infection [25,26], might
play a role. To determine the requirement for IL-17 and Th17
cells in mediating vaccine efficacy, we vaccinated mice deficient in
IL-17A, or their wild type congenic control mice. IL-17A-
deficiency abrogated vaccine-mediated efficacy (Fig. 4A). Of note,
in contrast to IFN-c deficiency, IL-17A deficiency did not
exacerbate the severity of infection in unvaccinated mice
(comparing survival of unvaccinated, deficient vs. wild type mice).
To determine if CD4+ T cells were the primary source of IL-17A
in mediating vaccine efficacy, CD4+ T cells from vaccinated or
control mice were cross-adoptively transferred into recipient mice
(IL-17A-deficient donor cells transferred to wild type recipient mice;
wild typedonor cells transferred to IL-17A-deficient recipient mice).
We also repeated the survival study in wild type and IL-17A
deficient mice that did not undergo adoptive transfer to serve as
positive and negative controls for the adoptive transfer study. Mice
were infected the day after adoptive transfer. Once again, the
vaccine improved the survival of the positive control wild type mice
but not the negative control IL-17A deficient mice (Fig. 4B).
Adoptive transfer of CD4+ cells from vaccinated wild type donor
mice improved the survival of IL-17A-deficient recipient mice (Fig.
4B). In contrast, transfer of CD4+ T cells from vaccinated IL-17A-
deficient donor mice to wild type recipient mice failed to improve
survival (Fig. 4C), confirming that CD4+ T cell derived IL-17A was
necessary to mediate vaccine efficacy.
Vaccination induced Th1, Th17, and Th1/17 cells in mice
To define the populations of cells induced by vaccination,
spleens and lymph nodes were harvested from vaccinated and
control mice two weeks following the boost. The cells were
stimulated ex vivo for 5 days with rAls3p-N. Analysis of
supernatants confirmed that cells from vaccinated mice produced
significantly more IFN-c and IL-17, as well as the neutrophil-
acting chemokines, KC and MIP-1a, than did cells from control
mice (Fig. 5A). IL-4 levels were not detectable in any supernatant
from control cells; levels were detectable at low levels (, 2 pg/ml)
in supernatants from 4 of the 8 mice in the vaccinated group.
However, IL-10 and IL-13 levels were higher in supernatants from
vaccinated than control mice. Levels of TGF-b and IL-6 were low
and not significantly different in supernatants from vaccinated or
control mice. Supernatants from stimulated, immune cells
markedly enhanced phagocytic killing of C. albicans and S. aureus
ex vivo, compared to supernatant from control cells (Fig. 5B).
Figure 2. Chemotherapy-induced neutropenia ablated vaccine
induced protection. Sixteen Balb/c mice per group were vaccinated
with rAls3p-N plus AlOH3 or AlOH3 alone, and boosted three weeks
later. Two weeks after the boost, half the mice were treated with
cyclophosphamide. Two days later the mice were infected with C.
albicans SC5314, 1.5610
5, C. albicans 15563, 7610
5, or MRSA LAC,
1.5610
7.* p ,0.05 for vaccinated vs. control by Log Rank test.
doi:10.1371/journal.ppat.1000703.g002
Figure 3. Phagocyte superoxide production is required for
vaccine protection. N=8 mice per group. Wild type C57BL/6 mice
were infected with 1.5610
5 C. albicans SC5314 or 2610
7 S. aureus LAC;
gp91
phox2/2 mice on a C57BL/6 background were infected with
1.5610
3 C. albicans or 10
7 S. aureus. A) Mice were vaccinated and
infected as above. *p,0.05 for wild type vaccinated vs. control by Log
Rank test. B) CD4+ T cells, 5610
6, from vaccinated or control, wild type
or gp91
phox2/2 mice were cross-adoptively transferred iv to recipient
mice 24 h prior to infection–wild type cells transferred to gp91
phox2/2
mice, and visa versa. *p,0.05 for wild type donor cells vaccinated vs.
control by Log Rank test.
doi:10.1371/journal.ppat.1000703.g003
Th1/Th17 Immunity to S. aureus and C. albicans
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strated that vaccination resulted in increased frequencies of Th1
(CD4+IFN-c+), Th17 (CD4+IL-17+), and Th1/17 (CD4+IFN-
c+IL-17+) cells in draining lymph nodes lymphocytes (Fig. 6 and
Figs. S2 and S3) compared to the frequencies in unvaccinated
mice. Murine CD4+CCR6- cells were enriched for the Th1
phenotype, and CD4+CCR6+ cells were enriched for the Th17
phenotype. However, a substantial proportion of CCR6+
splenocytes, and particularly CD4+CCR6+ lymphocytes, were
Th1/17 (IFNc+IL-17+) cells. The Th1/17 phenotype was
predominantly found in CD4+CCR6+ cells, not in the
CD4+CCR6- cells.
Vaccination resulted in enhanced phagocyte recruitment
and inflammatory cytokine production in the kidneys
during C. albicans and S. aureus iv infection
To confirm the in vivo biological relevance of the ex vivo
lymphocyte phenotypes, vaccinated or control mice were infected
via the tail vein with C. albicans or S. aureus 2 weeks following the
boost. At day 4 post-infection (the day before control mice were
anticipated to begin dying), burden of infection and cytokine levels
in homogenates of individually marked kidneys (primary target
organ) were determined. Levels of myeloperoxidase (MPO), which
is constitutively expressed at the protein level in neutrophils and
has been extensively used in previous studies to quantify
neutrophil influx into tissues during infection and inflammation
[27–31], were also measured.
Vaccination resulted in a ,10-fold reduction in kidney fungal
burden and ,5-fold reduction in kidney bacterial burden (Fig. 7A).
MPO levels were increased in vaccinated mice relative to control mice
infected with either organism (Fig. 7B). A recent study reported a 95%
correlation between organ fungal burden and neutrophil influx in
mice infected with different strains of C. albicans or C. dubliniensis [32].
Therefore, any enhanced neutrophil influx resulting from vaccination
could be offset by the diminished stimulus for neutrophil influx caused
by reduced fungal burden in the vaccinated mice. To isolate the
impact on MPO levels of vaccination, and not severity of infection, we
adjusted absolute MPO levels in individually marked organs for the
fungal or bacterial burden in those individual organs. Vaccination
resulted in a marked increase in neutrophil influx relative to the
infectious burden of organism in the tissues (Fig. 7B). By
histopathology, the inflammatory infiltrate was predominantly
Figure 4. CD4+ T cell derived IL-17A was required for vaccine
protection. A) Balb/c or IL-17A deficient mice on a Balb/c background
(n=8 per group) were vaccinated with rAls3p-N plus Alhydrogel or
Alhydrogel alone, with a boost at 3 weeks. Two weeks after the boost,
all mice were infected with 2.5610
5 C. albicans SC5314 or 2610
7 S.
aureus LAC. B) Balb/c mice or IL-17A deficient mice on a Balb/c
background, n=8 per group, were vaccinated with rAls3p-N plus
Alhydrogel or Alhydrogel alone. Two weeks after the boost, splenic and
lymph node CD4+ T cells, 5610
6, from vaccinated or control, wild type
or IL-17A-deficient mice were cross-adoptively transferred iv to
recipient mice, wild type donor to IL-17A deficient recipient, IL-17A
donor to wild type recipient, 24 h prior to infection with C. albicans
SC5314, 2.5610
5 inoculum. *p,0.05 for wild type donor vaccinated vs.
control by Log Rank test.
doi:10.1371/journal.ppat.1000703.g004
Figure 5. Vaccination primed lymphocytes to produce pro-
inflammatory, Th1/Th17 cytokines which enhanced phagocytic
killing of both organisms. A) Balb/c mice, n=8 per group, were
vaccinated with rAls3p-N plus Alhydrogel or Alhydrogel alone=Control.
Two weeks after the boost splenocytes and cervical and axillary lymph
node cells were harvested and incubated for 5 days with rAls3p-N.
Supernatant was harvested for determination of cytokine levels. Median
and interquartile ranges are shown. *p,0.03 vs. Control. B) RAW murine
macrophage cells or freshly harvested murine neutrophils were primed
with the above supernatants for four hours prior to incubation for one
additional hour with C. albicans SC5314 (20:1 RAW to C. albicans; 10:1
neutrophils to C. albicans)o rS. aureus LAC (5:1 RAW to S. aureus; 10:1
neutrophils to S. aureus). The culture wells were overlaid with agar and
colonies counted the following day. Percent killing reflects reduction in
colony forming units compared to number of organisms added to the
wells. Median and interquartile ranges are graphed. *p,0.05 for
immune vs. control supernatant.
doi:10.1371/journal.ppat.1000703.g005
Th1/Th17 Immunity to S. aureus and C. albicans
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scoring of histopathology sections by a blinded pathologist to estimate
neutrophil influx into tissues was concordant with the quantitative
MPO levels.
Concordant with ex vivo cytokine measurements, absolute levels of
IFN-c, IL-17,and the neutrophil-acting CXC chemokine, KC, were
higher in the kidneys of vaccinated versus control mice (p,0.05 for
all comparisons ofvaccinated vs.control levelsfor allthree cytokines,
in mice infected with C. albicans or S. aureus). After adjusting for
infectious burden in individual organs, vaccination markedly
increased cytokine levels relative to infectious burden (Fig. 7C).
Histopathology confirmed a marked increase in organism
burden in the vaccinated mice versus control mice infected with
either organism (Fig. 8). Numerous microabscesses with hyphal
and pseudohyphal elements were scattered throughout the kidneys
of control mice infected with C. albicans. Microabscesses were also
found in the kidneys of vaccinated mice, but most of the abscesses
had no fungal elements visible, and those few abscesses with fungal
elements contained blastospores or small hyphal fragments.
Control mice infected with S. aureus had large renal abscesses
with numerous gram positive cocci on Gram stain. Vaccinated
mice also had renal abscesses with extensive neutrophil influx, but
in most abscesses fewer staphylococcal organisms were seen on
Gram stain in vaccinated than control mice (Fig. 8).
Discussion
One hypothesis regarding the failure to date to develop an
effective vaccine against S. aureus or Candida has been the need to
simultaneously disrupt multiple virulence factors for such complex
pathogens, whereas most vaccines to date have targeted only one
virulence factor [33,34]. However, we have previously confirmed
that humoral immunity is neither necessary nor sufficient for
rAls3p-N vaccine-induced protection against either organism
[6,7]. Furthermore, homozygous disruption of ALS3 in C. albicans
does not result in a loss of pathogenicity in vivo in mice, so the
protection mediated by the rAls3p-N vaccine is not the result of
abrogation of Als3p virulence functions. The current study
confirms that vaccination can be effective by targeting the
organism for destruction by increasing the quantity and microbi-
cidal functions of innate phagocytic effectors at the site of
infection, irrespective of affecting virulence functions in the
organism. Therefore, potential vaccine antigens need not be
restricted to microbial virulence factors, and can be expanded to
include any target antigen which results in a potent Th1 and/or
Th17 immune response against the organism. These data are
concordant with the established role of Th17 cells in mediating
protection following immunization of mice against Mycobacterium
tuberculosis, Helicobacter pylori and Pseudomonas aeruginosa [31,35,36].
In unvaccinated animals, deficiency in IFN-c but not IL-17A
exacerbated the severity of iv infection caused by both S. aureus and
C. albicans. These results are concordant with recent studies
demonstrating that IL-17-deficient mice were not more susceptible
to bloodstream infection caused by S. aureus [37] or invasive gastric
infection caused by C. albicans [38]. Furthermore, a recent study
reported that abrogation of the dectin-2 receptor blocked Th17
induction by C. albicans in mice, but despite the lack of a Th17
response did not affect the ability of mice to clear fungus from
Figure 6. Vaccination primed Th1, Th17, and Th1/17 cells in draining lymph nodes. Balb/c mice, n=4 per group, were vaccinated with
rAls3p-N plus Alhydrogel or Alhydrogel alone=Control. Two weeks after the boost cervical and axillary lymph node cells were harvested and
incubated for 5 days with rAls3p-N, followed by 6 h with PMA/ionomycin and monensin. Cells were fixed, permeabilized, and stained for CD4, CCR6,
IFN-c, or IL-17. Intracellular cytokine analysis was conducted by flow cytometry. ‘‘All Lymphocytes’’ were gated based on size by FSC and density by
SSC; CD4+ and CCR6+ lymphocytes were further gated from the ‘‘All Lymphocyte’’ population by fluorescence signal indicating surface expression of
these markers. Median and interquartile ranges are shown. *P,0.05 vs. Control.
doi:10.1371/journal.ppat.1000703.g006
Th1/Th17 Immunity to S. aureus and C. albicans
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indicate that Th17 cells/IL-17A are not necessary for normal
murine host defense against disseminated candidiasis.
In contrast, IL-17 has been shown to be critical for host defense
against cutaneous and oropharyngeal infections caused by S. aureus
[37] and C. albicans [40], respectively. Furthermore, our results are
discordant with the previous finding that IL-17 receptor-deficiency
moderately exacerbated the severity of bloodstream infection
caused by C. albicans [41]. The lack of a requirement for IL-17A to
mediate normal host defense against disseminated candidiasis
likely reflects the ability of IL-17F, which also activates the
common IL-17 receptor, to complement an IL-17A deficiency.
Differences in C. albicans infecting strain and mouse host strain
may also account for differences between our study and the prior.
However, a critical point is that IL-17F could not compensate for
the requirement for IL-17A in mediating protective, vaccine-
induced, adaptive immunity, since IL-17A deficiency abrogated
vaccine efficacy.
We confirmed that the rAls3p-N vaccine specifically primed
splenic and lymph node lymphocytes to produce high levels of
both IFN-c and IL-17, as well as the neutrophil chemokines, KC
and MIP-1a (the latter of which is chemotactic for both
mononuclear cells and neutrophils [42–47]). The predominant
IFN-c expression in lymph nodes was found in CCR6- Th1 cells
which did not produce IL-17 (CD4
+CCR6
2IFN-c
+IL-17
2), and
the predominant IL-17 expression in lymph nodes was found in
CCR6+ cells. However, we also found substantial numbers of
Th1/17 cells, which met or exceeded the frequency of Th17 cells,
in the CD4+CCR6+ fraction. The Th1/17 cells were found
virtually exclusively in the CCR6+ fraction, and none were found
in the CD4+CCR6- fraction. Recent studies have indicated that
yeast mannosylated proteins prime Th17 cells via activation of the
mannose receptor [48], and that O-linked mannoproteins can
activate IFN-c production via ligation of TLR4 [49]. Since the
rAls3p-N protein has O-linked yeast high mannose groups, co-
ligation of the mannose receptor and TLR4 on antigen presenting
cells may enable induction of Th1, Th17, and Th1/17 cells. The
role of specific antigen presenting cells in priming lymphocytes for
Th1, Th17, or dual Th1/17 responses is currently under
investigation.
We found variations in the total number of surviving mice from
experiment to experiment, ranging from as high as 87% to as low
as 12.5%. Variations in outcome are most likely accounted for by
variations in infectious inoculum and infecting strain. Our
challenge model, using the standard SC5314 clinical isolate of C.
albicans, is extremely rigorous, and is considerably more rigorous
than challenge with other clinical strains of C. albicans [6,50,51], as
evidenced by the superior efficacy seen in the current study with
another clinical bloodstream isolate of C. albicans (15563). We have
previously shown that mice infected with the inocula of SC5314
used in these experiments die of overwhelming septic shock [52].
Candidal septic shock causes .50% mortality in humans despite
treatment with antifungal therapy [4]. Hence, achievement of
survival approaching 50% by vaccination alone is felt to reflect
meaningful protection. Furthermore, the experiment in which
12.5% survival was seen in the vaccinated arm was an adoptive
Figure 7. Vaccination reduced infectious burden and stimulated neutrophil influx by MPO and pro-inflammatory cytokine levels in
kidneys. Balb/c mice, n=8 per group, were vaccinated with rAls3p-N plus Alhydrogel or Alhydrogel alone. Two weeks after the boost, mice were
infected iv with C. albicans SC5314, 2610
5,o rS. aureus LAC, 3610
7. Four days after infection, individually marked kidneys (primary target organ of
infection for both models) were harvested, homogenized, and quantitatively cultured (A). MPO levels (B) and cytokine levels (C) in organ
homogenates were measured by ELISA. MPO levels are shown both as raw values in ng/g of kidney tissue, and also normalized to burden of infection
in each individually marked organ in fg/g tissue/CFU per organ. Cytokine levels are shown normalized to organ CFU burden. Median and interquartile
ranges are shown. *p,0.05 vs. Control by Mann Whitney U test.
doi:10.1371/journal.ppat.1000703.g007
Th1/Th17 Immunity to S. aureus and C. albicans
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were transferred into IL-17A-/- recipient mice. Thus, while IL-
17A production from CD4+ immune T cells can transfer
protection, production of IL-17A by other cell types may be
required to achieve maximal protection. Specifically, we previ-
ously found that immune CD8+ T cells could transfer protection
against S. aureus [7], and macrophages or dendritic cells can
produce pro-inflammatory cytokines such as IFN-c, suggesting
that these cell types may play an adjunctive role and be required
for full vaccine-mediated protection.
We previously reported that cyclophosphamide-induced neu-
tropenia did not completely abrogate vaccine-induced protection
during subsequent disseminated candidiasis [53]. In contrast, in
the current study, we did find total abrogation of protection
against both candidal strains and against S. aureus. The prior study
used a different but related vaccine immunogen, rAls1p-N, instead
of rAls3p-N. As well, the prior study used Complete Freund’s
Adjuvant (CFA), not Al(OH)3. The greater efficacy of the former
adjuvant may account for the residual efficacy found in
neutropenic mice in the former study.
S. aureus and C. albicans express adhesins on their cell surface
which possess similar three dimensional shapes [54] and which
bind to similar endovascular surfaces (e.g. endothelial cells and
subendothelial matrix proteins) and medically relevant plastics
[54,55]. Given these similar virulence mechanisms, it is not
surprising that the organisms also infect patients with similar risk
factors, including post-operative and trauma patients, patients with
central venous catheters, patients on hemodialysis, and patients
with compromised phagocytic host defense mechanisms [4,56,57].
Finally, our data demonstrate that the host defends itself against
both infections by similar mechanisms, and that adaptive
immunity to both organisms required CD4+ T cell production
of both IFN-c and IL-17A.
In summary, the rAls3p-N vaccine improved outcomes in
mouse models of iv S. aureus and C. albicans infection by inducing
upstream, pro-inflammatory, Th1, Th17, and Th1/17 lympho-
cytes, which enhanced recruitment and activation of neutrophils in
infected tissues, thereby reducing tissue infectious burden. Thus,
vaccination showed a potential to protect against both infections
by targeting the microbes for enhanced destruction by innate
effector cells, irrespective of neutralization of microbial virulence
factors. Therefore, potential vaccine antigens need not be
restricted to microbial virulence factors, and can be expanded to
include any target antigen which results in a potent Th1 and/or
Th17 immune response against the organisms.
Methods
Organisms and mouse strains
C. albicans SC5314 was supplied by W. Fonzi (Georgetown
University), and S. aureus LAC, a USA300 MRSA clinical isolate,
was provided by Frank Deleo (NIAID/NIH). C. albicans 15563 is a
clinical bloodstream isolate from a patient at Harbor-UCLA
Medical Center which is also virulent in our murine model [50].
Candida was serially passaged three times in yeast peptone dextrose
broth (Difco) at room temperature prior to infection. S. aureus was
grown overnight at 37uC in BHI broth, and then passaged for
4 hours at 37uC in fresh BHI broth.
Female Balb/c or C57BL/6 mice were obtained from Taconic
Farms (Bethesda, MD). Congenic IL-17A deficient mice on a
Balb/c background were obtained from Y. Iwakura (University of
Tokyo) [58]. Vaccinated mice were infected via the tail vein with
the appropriate inocula of C. albicans blastospores or S. aureus
organisms in PBS, as previously described [7,52]. In some
experiments, mice were made neutropenic by treatment with
230 mg/kg cyclophosphamide 2 days prior to infection, a regimen
which results in profound neutropenia for approximately one week
[59,60]. All procedures involving mice were approved by the Los
Angeles Biomedical Research Institute animal use and care
committee, following the National Institutes of Health guidelines
for animal housing and care.
Immunization protocols
rAls3p-N (amino acids 17 to 432 of Als3p) was produced in
Saccharomyces cerevisiae and purified by Ni-NTA matrix affinity
purification as previously described [61]. Mice were immunized by
subcutaneous (SQ) injection of 300 mg of rAls3p-N in 0.1%
Al(OH)3 (Alhydrogel, Brenntag Biosector, Frederikssund, Den-
Figure 8. Unvaccinated mice had less neutrophil influx relative
to fungal and bacterial burden than vaccinated mice. Represen-
tative histopathological sections from kidneys from 2 mice per group are
shown. Control mice infected with C. albicans had multiple abscesses
with visible hyphae and pseudohyphae throughout the kidneys.
Vaccinated mice infected with C. albicans had abscesses, but with far
less fungus visible. Numerous abscesses were seen in both vaccinated
and control mice infected with S. aureus. However, overall the abscesses
in the control mice infected with S. aureus had considerably more
bacteria by gram stain than the abscesses in the vaccinated mice.
Sections were stained by PAS (for C. albicans) or H&E (to show the
neutrophil influx and the extent of tissue necrosis) and Gram stain (to
show S. aureus dark purple clusters). Magnification=10006.
doi:10.1371/journal.ppat.1000703.g008
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schedule. Some mice were boosted at 21 days. Mice were infected
two weeks following the boost.
Adoptive transfer and passive immunization
Serum and splenic lymphocytes were harvested from vaccinated
or control mice, as we have previously described [62]. Lymph
node lymphocytes were harvested from cervical and axillary lymph
nodes, based on pilot studies with Evans Blue dye lymph node
mapping demonstrating that SQ vaccination at the base of the
neck drained primarily to these lymph nodes. For adoptive
transfers, splenic and lymph node lymphocytes were pooled.
CD4+ T lymphocytes were purified by use of the IMag system (BD
Pharmingen), as we have described [6,7]. Purified lymphocytes
(5610
6 per mouse) were administered iv to congenic, unvaccinated
recipient mice. Transferred cell populations were $95% pure by
flow cytometric analysis. Mice were infected via the tail-vein with
C. albicans SC5314 24 h after lymphocyte adoptive transfer.
Intracellular cytokine analysis and cytokine supernatant
analysis
Intracellular cytokines from lymphocytes were analyzed based
on a modification of our previously described method [62]. In
brief, cervical and axillary lymph nodes and spleens were dissected
from vaccinated or control mice and passed through 70 mm filters.
Cells were stimulated for 5 days with rAls3p-N (12.5 mg/ml) in
complete media (RPMI 1640, 50 U/ml penicillin, 50 mg/ml
streptomycin, 2 mM L-glutamine, 10% FBS, 5 mM 2-ME) in 96
well plates. PMA (50 ng/ml), ionomycin (1 mM), and monensin
(10 mg/ml) were added during the final 6 hours of culture.
Supernatant was harvested prior to adding monensin for analysis
of cytokine content using Cytometric Bead Array Flex kits (BD
Pharmingen, La Jolla, CA) or ELISA (for IL-6, TGF-b, and IL-
13), per the manufacturer’s instructions. Cells were stained on ice
with PerCP-anti-CD4 and Alexa647-anti-CCR6 (BD Pharmingen,
San Diego), or their isotype control antibodies. The cells were
fixed and permeabilized as previously described [62]. Intracellular
cytokines were stained with rat FITC-anti-mouse IFN-c and PE-
anti-IL-17, or their isotype controls (BD Pharmingen). Four-color
flow cytometry was performed on a Becton-Dickinson FACScan
instrument calibrated with CaliBRITE beads (Becton Dickinson,
San Jose, CA) using FACSComp software as per the manufactur-
er’s recommendations. Data for each sample were acquired until
10,000 CD4
+ lymphocytes were analyzed. Th1 cells were defined
as CD4
+IFNc
+IL-17
2, Th17 cells defined as CD4
+IFN-c
2IL-17
+,
and Th1/17 cells defined CD4
+IFNc
+IL-17
+.
Killing assay
The killing assay for both C. albicans and S. aureus was modified
based on our well-described assay [59,60]. In brief, RAW murine
macrophage cells or murine neutrophil cells were grown in DMEM
plus 10% fetal bovine serum. Fresh murine neutrophils were
harvested by dextran sedimentation of whole, heparanized blood,
followed by centrifugation over Ficoll Hypaque at 500 g for
10 minutes. The RAW cells or neutrophils were added into 24 well
plates, the media in the wells was aspirated and the RAW cells or
fresh neutrophils were cultured for 4 hours in 10% conditioned
media (from vaccinated or control splenic and lymph node
lymphocytes exposed to rAls3p-N for 5 days) plus 90% complete
media (RPMI + 10% FBS). The conditioned media was then
aspirated, and the microorganisms added to the wells in fresh
DMEM plus 10% fetal bovine serum. Microorganisms were added
to the wells at a ratio of 20:1 RAW cells to C. albicans, 5:1 RAW cells
to S. aureus, or 10:1 fresh neutrophils to C. albicans or S. aureus. Media
for the wells containing S. aureus contained no antibiotics. The cells
were incubated at 37uC for 1 h, at which point 4% blood heart
infusion (BHI) agar was directly added to the wells. Plates were
incubated overnight at 37uC and colony forming units (CFUs)
counted in each well. Killing was defined as the percent reduction
CFUs in wells containing co-cultures of phagocytes cells and
microorganisms compared to wells just containing microorganisms.
Tissue burden, whole organ cytokines, myeloperoxidase
(MPO), and histopathology
On day 4 post-infection, kidneys (primary target organ) were
harvested and homogenized in saline with protease inhibitors
(pepstatin, leupeptin, and PMFS). For determination of infectious
burden, organ homogenates were quantitatively cultured on
Sabourad dextrose agar for C. albicans or tryptic soy agar for S.
aureus. Whole organ cytokines were analyzed from kidney
homogenates by ELISA (R&D Systems) or Cytometric Bead
Array Flex kit for KC (BD Pharmingen, La Jolla, CA), per the
manufacturer’s instructions. MPO levels were determined by
ELISA (Hycult Biotechnology, Uden, Netherlands) of whole organ
homogenates. For histopathology, organs were fixed in zinc-
buffered formalin, embedded in paraffin, sectioned, and stained
with PAS for fungi and H&E and Gram stain for bacteria.
Statistics
The non-parametric Log Rank test was utilized to determine
differences in survival times. The Wilcoxon Rank test was used to
compare cytokines, MPO levels, and organ burden across groups.
P,0.05 was considered significant.
Supporting Information
Figure S1 Chemotherapy-induced neutropenia ablated vaccine
induced protection against a second C. albicans clinical isolate.
Sixteen Balb/c mice per group were vaccinated with rAls3p-N
plus Al(OH)3 or Al(OH)3 alone, and boosted three weeks later.
Two weeks after the boost, half the mice were treated with
cyclophosphamide. Two days later the mice were infected with C.
albicans 15563 (7x10
5). *p,0.05 for vaccinated vs. control by Log
Rank test.
Found at: doi:10.1371/journal.ppat.1000703.s001 (1.28 MB TIF)
Figure S2 FACS plots for gating on Th1, Th17, and Th1/17
cells in draining lymph nodes. Shown here are representative
FACS plots, corresponding to the data in Fig. 6 of the manuscript,
demonstrating acquisition gates based on size (FSC), density (SSC),
or expression of CD4 or CCR6 on the cell surface.
Found at: doi:10.1371/journal.ppat.1000703.s002 (1.85 MB TIF)
Figure S3 Vaccination primed Th1, Th17, and Th1/17 cells in
draining lymph nodes. FACS plots demonstrating analysis of
cytokine expression among lymphocytes using the gates shown in
Fig. S2.
Found at: doi:10.1371/journal.ppat.1000703.s003 (1.52 MB TIF)
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